Schonfeld Strategic Advisors LLC - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 233 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
Schonfeld Strategic Advisors LLC ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2023$852,804
+252.1%
121,137
+474.1%
0.01%
+250.0%
Q4 2022$242,228
-90.8%
21,100
-89.9%
0.00%
-90.9%
Q3 2022$2,621,000
+44.6%
207,972
+21.4%
0.02%
+22.2%
Q2 2022$1,813,000
-61.2%
171,296
-40.5%
0.02%
-57.1%
Q1 2022$4,678,000
+534.7%
287,700
+440.8%
0.04%
+500.0%
Q4 2021$737,000
+74.2%
53,200
+80.6%
0.01%
+75.0%
Q3 2021$423,000
-74.5%
29,459
-72.0%
0.00%
-77.8%
Q2 2021$1,661,000
+726.4%
105,087
+433.3%
0.02%
+800.0%
Q1 2021$201,000
-69.1%
19,704
-77.5%
0.00%
-77.8%
Q4 2020$650,000
-21.7%
87,391
-63.8%
0.01%
-43.8%
Q3 2020$830,000
-47.9%
241,411
-27.8%
0.02%
-23.8%
Q2 2020$1,594,000
+16.4%
334,456
-15.8%
0.02%
-36.4%
Q4 2019$1,370,000
-47.5%
397,266
-56.4%
0.03%
-57.1%
Q3 2019$2,611,000
-69.2%
911,300
-59.2%
0.08%
-74.2%
Q2 2019$8,467,000
+9413.5%
2,233,700
+20206.4%
0.30%
+9866.7%
Q4 2018$89,000
-78.7%
11,000
-79.9%
0.00%
-84.2%
Q3 2018$418,000
+450.0%
54,800
+299.3%
0.02%
+137.5%
Q2 2017$76,000
-88.2%
13,723
-82.1%
0.01%
-87.5%
Q1 2017$643,00076,5830.06%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
VHCP Management, LLC 1,744,356$18,455,0009.59%
RA Capital Management 4,347,456$45,996,0003.30%
Cormorant Asset Management, LP 1,168,000$12,357,0002.84%
Baker Brothers Advisors 5,867,031$62,073,0000.79%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 907,920$9,606,0000.39%
QVT Financial LP 525,734$5,562,0000.32%
EAM Investors, LLC 114,548$1,212,0000.22%
FRANKLIN STREET ADVISORS INC /NC 93,000$984,0000.20%
THB ASSET MANAGEMENT 301,529$3,190,0000.19%
TPG Group Holdings (SBS) Advisors, Inc. 1,162,269$12,297,0000.13%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders